Dingell generic drug probe
Executive Summary
House Commerce/Oversight & Investigations Subcommittee plans to interview more than the 60 FDA employees it had initially targeted for questioning in its investigation into the agency's generic drug approval process. The subcommittee, chaired by Rep. Dingell (D-Mich.), expects to finish first round of interviews, including the 60 FDAers, during the week ending April 8. Dingell has said that the interviews are necessary due to the expansion of the generic drug approval inquiry launched last summer ("The Pink Sheet" March 20, p. 3).
You may also be interested in...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: